In March 2020 Inceptua licensed the global commercial rights of Jetrea from Oxurion NV.

Jetrea (ocriplasmin) ) is a prescription intravitreal injection and must be administered by a qualified eye specialist.

Jetrea is a truncated form of human plasmin and is a first-in-class pharmacological vitreolysis therapy approved to treat patients with symptomatic vitreomacular adhesion or vitreomacular traction.

Please always consult local prescribing information and labelling text before use.

For more information about Jetrea please refer to the prescribing information: European Medicines Agency

Privacy notice

Health Care Professionals and Adverse Event Report Privacy Notice.

Medical Information

If you would like to speak to a medical representative, please contact:

+49 30 1202 1381

Safety and adverse events

Patient safety is a key priority for us. For any suspected adverse drug reactions associated with Jetrea, please contact:

+49 30 1202 1381

Inceptua Pharma Medicines Access Policy